Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Theriva Biologics Inc (TOVX)

$0.23 +0.00 (1.46%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	7.76M
Revenue (ttm)	0.00
Net Income (ttm)	-23.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.11

Volume	3,202,100
Avg Vol	14,345,958
Day's Range	N/A - N/A
Shares Out	33.74M
Stochastic %K	50%
Beta	0.47
Analysts	Strong Sell
Price Target	$2.50

Company Profile

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for trea...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 417 4364

Website: therivabio.com

Address:

9605 Medical Center Drive, Suite 270, Rockville, United States

Thess5 Apr. 5 at 8:51 AM

$TOVX .10 R/S

0 · Reply

Homer_Simpson82 Apr. 5 at 6:45 AM

$TOVX Expert3😅

0 · Reply

Themaster24 Apr. 5 at 2:00 AM

$TOVX 3$ soon

0 · Reply

Alfahker Apr. 5 at 2:00 AM

$TOVX

0 · Reply

Duskfall Apr. 4 at 6:17 PM

$TOVX 💯

0 · Reply

Duskfall Apr. 4 at 6:15 PM

Happy Easter everyone! I hope you took advantage of the dip. Starting next week, this will be working 💯 $VXRT $BTAI $AEMD $TOVX $CGTX

0 · Reply

BadyBady Apr. 3 at 1:37 PM

$TOVX “Is there talk/rumors about a merger or a partnership?

0 · Reply

cbachand Apr. 3 at 12:17 AM

$TOVX This is an excellent review of TOVX. https://www.youtube.com/watch?v=lBM0c4TXSMk&t=51s

3 · Reply

dogood Apr. 3 at 12:08 AM

$TOVX is everyone average above $3??

0 · Reply

Homer_Simpson82 Apr. 2 at 11:51 PM

$TOVX RS no squezze👌👌

0 · Reply

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Oct 24, 2025, 2:31 PM EDT - 5 months ago

Theriva Biologics Provides Response to Unusual Market Action

Oct 16, 2025, 8:11 AM EDT - 6 months ago

Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds

Oct 6, 2025, 8:00 AM EDT - 6 months ago

Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Aug 11, 2025, 8:00 AM EDT - 8 months ago

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

May 14, 2025, 8:40 AM EDT - 11 months ago

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

May 8, 2025, 4:30 PM EDT - 11 months ago

Theriva Biologics Announces Closing of $7.5 Million Public Offering

May 7, 2025, 9:17 AM EDT - 11 months ago

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Mar 19, 2025, 8:10 AM EDT - 1 year ago

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Mar 6, 2025, 4:10 PM EST - 1 year ago

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Mar 5, 2025, 4:05 PM EST - 1 year ago

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Dec 5, 2024, 8:00 AM EST - 1 year ago

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Sep 26, 2024, 9:06 PM EDT - 1 year ago

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

Aug 16, 2024, 4:05 PM EDT - 1 year ago

Theriva Biologics Announces Reverse Stock Split

Jul 31, 2024, 8:15 AM EDT - 1 year ago

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

May 23, 2024, 8:15 AM EDT - 2 years ago

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

May 14, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference

May 7, 2024, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

Apr 25, 2024, 8:15 AM EDT - 2 years ago

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annua

$Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma$